These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 20635141)
1. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Li C; Guo Y; Xie W; Li X; Janokovic J; Le W Neurochem Res; 2010 Oct; 35(10):1546-56. PubMed ID: 20635141 [TBL] [Abstract][Full Text] [Related]
2. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. Li C; Biswas S; Li X; Dutta AK; Le W J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619 [TBL] [Abstract][Full Text] [Related]
3. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914 [TBL] [Abstract][Full Text] [Related]
4. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767 [TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. Xie W; Li X; Li C; Zhu W; Jankovic J; Le W J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845 [TBL] [Abstract][Full Text] [Related]
6. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Du F; Li R; Huang Y; Li X; Le W Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585 [TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease. Du Y; Zhang X; Tao Q; Chen S; Le W Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907 [TBL] [Abstract][Full Text] [Related]
8. Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease. Konieczny J; Jantas D; Lenda T; Domin H; Czarnecka A; Kuter K; Śmiałowska M; Lasoń W; Lorenc-Koci E Neurotox Res; 2014 Oct; 26(3):255-73. PubMed ID: 24842651 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
10. The neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement in models of Parkinson's disease. Bae N; Ahn T; Chung S; Oh MS; Ko H; Oh H; Park G; Yang HO J Ethnopharmacol; 2011 Mar; 134(2):313-22. PubMed ID: 21172413 [TBL] [Abstract][Full Text] [Related]
11. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease. Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363 [TBL] [Abstract][Full Text] [Related]
12. Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson's disease. Dong AQ; Yang YP; Jiang SM; Yao XY; Qi D; Mao CJ; Cheng XY; Wang F; Hu LF; Liu CF Acta Pharmacol Sin; 2023 Jan; 44(1):32-43. PubMed ID: 35896696 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776 [TBL] [Abstract][Full Text] [Related]
14. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. Zhang Z; Li X; Xie WJ; Tuo H; Hintermann S; Jankovic J; Le W CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):768-73. PubMed ID: 22483304 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Anderson DW; Neavin T; Smith JA; Schneider JS Brain Res; 2001 Jun; 905(1-2):44-53. PubMed ID: 11423078 [TBL] [Abstract][Full Text] [Related]
16. Adaptive changes in autophagy after UPS impairment in Parkinson's disease. Shen YF; Tang Y; Zhang XJ; Huang KX; Le WD Acta Pharmacol Sin; 2013 May; 34(5):667-73. PubMed ID: 23503475 [TBL] [Abstract][Full Text] [Related]
17. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Zhu W; Xie W; Pan T; Xu P; Fridkin M; Zheng H; Jankovic J; Youdim MB; Le W FASEB J; 2007 Dec; 21(14):3835-44. PubMed ID: 17690154 [TBL] [Abstract][Full Text] [Related]